Trial Profile
A real world, retrospective study to evaluate use of Secukinumab by describing demographic, clinical and treatment characteristics in patients with Ankylosing Spondylitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jun 2018
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- 13 Jun 2018 According to a Novartis media release, data from this study will be presented at the Annual European Congress of Rheumatology (EULAR 2018).
- 05 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism